Synthemax cuts hESC production cost say Geron and Corning
New Synthemax synthetic growth matrix promises improved scalability for large-scale hESC production which, say developers Geron and Corning, will cut cost of cell therapy manufacture.
The US FDA wants to boost the production of cell-based viral vaccines and says new guidance will help manufacturers.
Asterand gains GLP accreditation at UK laboratory
Asterand has gained GLP accreditation at its UK lab, enabling it to support regulatory submissions and furthering its goal of becoming a fully integrated human tissue service provider.
Covance’s R&D partnership with Lilly expands
Covance will provide US drug major Eli Lilly with bioproduct analytical testing services under an expansion of the firms’ year-old R&D collaboration.
Merck KGaA to buy Millipore for €5bn
German pharmaceutical firm Merck KGaA says proposed Millipore acquisition will transform its chemicals unit and give it a more balanced business profile.
SAFC Pharma is preparing for the shift towards cell culture-based vaccines, while still supplying and growing in the traditional sector, to ensure it can grow in coming years, according to a company director.
Sandoz opens Slovenian biosimilars production plant
Lek has opened a 430m² modified protein manufacturing facility in Slovenia to produce epoetin alfa drug substance for use in the biosimilars marketed by its parent company, Sandoz.
Lilly’s Puerto Rico API plant issued with FDA warning letter
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
Dishman teams with Codexis’ for cost saving enzymatic API tech
Codexis’ enzymatic biocatalysis technology offers numerous processing and cost advantages for API and chemical intermediate manufacture says Dishman CRAMS unit president Nick Green.
RecipharmCobra Biologics launches today
RecipharmCobra Biologics (RCB) launched today as a specialist biologics contract development and manufacturing organization (CDMO).
H1N1 adjuvants help SAFC in Q4; Sigma sales down in 2009
Revenues fell 3 per cent in 2009 at SAFC but pharmaceutical sector demand for vaccine manufacturing products helped firm finish year with six months of growth.
Russia invests in cancer nanodrug capacity and safety
Rusnano, the group set up to promote Russia’s nanotechnology infrastructure, says nanodrug development partnership will improve patient access and cut cancer death rates across the country.
Parexel allies with Proteome to boost biomarker offering
Parexel has formed an alliance with Proteome Sciences to enhance its biomarker capabilities, allowing it to help clients make earlier assessments of new compounds in development.
Cali OK for Avrio manufacturing plant
US CDMO Avrio Biopharmaceuticals’ new aseptic fill-and-finish facility in Irvine, California has been approved for the manufacture of biologics by state drug regulators.
MDRNA’s formulation stable after 12 months
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.